EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Minimally invasive lobectomy following pathologic complete response to neoadjuvant Lorlatinib in ALK-positive squamous cell carcinoma

Alexandra Molkova, Ruifeng Li, Shuben Li

Interdisciplinary CardioVascular and Thoracic Surgery · 22.10.2026

DOI: 10.1093/icvts/ivag280 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Interdisciplinary CardioVascular and Thoracic Surgery, online erschienen am 22.10.2026. Verfasst von Alexandra Molkova und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ALK rearrangements are uncommon in lung squamous cell carcinoma, and neoadjuvant ALK inhibition remains investigational. We report a 52-year-old never-smoking female with stage IIIB ALK-positive squamous cell carcinoma treated with neoadjuvant lorlatinib for 12 weeks. Serial imaging demonstrated a 61% reduction in tumor size with nodal regression. The patient subsequently underwent a uniportal video-assisted thoracoscopic (uVATS) lobectomy, and final pathology revealed a complete pathological response (pCR) of the primary tumor. This case highlights the feasibility and safety of minimally invasive anatomical lung resection following neoadjuvant lorlatinib despite treatment-related hilar fibrosis and vascular–bronchial adhesions.

Schlagwörter

Stichwörter der Autor:innen

ALK rearrangementcase reportlorlatinibneoadjuvant therapysquamous cell carcinoma

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
  • National Clinical Research Center for Respiratory Disease; State Key Laboratory of Respiratory Disease; Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou…

Zitieren

APA

Molkova, A., Li, R., & Li, S. (2026). Minimally invasive lobectomy following pathologic complete response to neoadjuvant Lorlatinib in ALK-positive squamous cell carcinoma. Interdisciplinary CardioVascular and Thoracic Surgery. https://doi.org/10.1093/icvts/ivag280

Vancouver

Molkova A, Li R, Li S. Minimally invasive lobectomy following pathologic complete response to neoadjuvant Lorlatinib in ALK-positive squamous cell carcinoma. Interdisciplinary CardioVascular and Thoracic Surgery. 2026. doi:10.1093/icvts/ivag280

BibTeX
@article{Molkova2026,
  author = {Molkova, Alexandra and Li, Ruifeng and Li, Shuben},
  title = {Minimally invasive lobectomy following pathologic complete response to neoadjuvant Lorlatinib in ALK-positive squamous cell carcinoma},
  journal = {Interdisciplinary CardioVascular and Thoracic Surgery},
  year = {2026},
  doi = {10.1093/icvts/ivag280}
}
Kostenlos starten →